Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Is Falling Today

By Keith Speights – Sep 2, 2020 at 12:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The closing of an acquisition diluted the biotech's shareholders, but that's not the whole story.

What happened

Shares of Sorrento Therapeutics (SRNE 2.44%) were trading 5.5% lower as of 12:22 p.m. EDT on Wednesday. The morning's declines came after the company announced earlier that it had completed its acquisition of SmartPharm Therapeutics on Tuesday.

So what

Investors have known about Sorrento's plans to acquire SmartPharm since July 24. Were they disappointed with the decision? Nope. The biotech stock soared by more than 150% over the next few weeks before giving up the gains.

Drawing of coronavirus on a yellow sticky note with a dollar sign written in chalk underneath the note

Image source: Getty Images.

So why did Sorrento's shares sink Wednesday? Part of the reason relates to how it's paying for the acquisition. The company issued around 1.76 million new shares to give to SmartPharm stockholders to close the deal, which diluted the value of the previously existing shares.

But the number of new shares issued represents less than 1% of Sorrento's outstanding shares, so clearly, the closing of the SmartPharm deal wasn't the only driver of Wednesday's drop. It appears to be the continuation of a downward trend that began more than three weeks ago, stemming from the growing concerns among investors about Sorrento's prospects in the fast-moving COVID-19 therapeutics and vaccine markets.

Now what

Sorrento needs a clear win to turn things around -- and the FDA could hand it one or two in the not-too-distant future. The biotech is awaiting decisions from the regulator on an emergency use authorization for its COVI-TRACK novel coronavirus antibody test and on allowing it to initiate a phase 1 clinical study of its experimental antibody therapy, COVI-GUARD.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Sorrento Therapeutics Stock Quote
Sorrento Therapeutics
$1.26 (2.44%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.